Imsidolimab is a monoclonal antibody commercialized by AnaptysBio, with a leading Phase III program in Generalized Pustular Psoriasis (GPP). According to Globaldata, it is involved in 10 clinical trials, of which 4 were completed, 3 are ongoing, and 3 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Imsidolimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Imsidolimab is expected to reach an annual total of $13 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Imsidolimab (ANB-019) is under development for the treatment of generalized pustular psoriasis (GPP). It is administered through the subcutaneous and intravenous route. The drug candidate acts by targeting the interleukin-36 receptor (IL-36R). It is developed based upon somatic hypermutation (SHM) Platform.
It was under development for the treatment of palmo-plantar pustular psoriasis (PPP), hidradenitis suppurativa, palmoplantar pustulosis (PPP),acne vulgaris, Ichthyosis and EGFRi/MEKi therapy mediated acneiformrash.
AnaptysBio is a clinical-stage biotechnology company that focuses on the development of antibody candidates for the treatment of atopic dermatitis, ovarian cancer, lung cancer, asthma, psoriasis, inflammation, and other autoimmune indications. The company develops its product candidates through its proprietary antibody discovery technology platform that is based on somatic hypermutation (SHM). The company has various product candidates under development for the treatment of moderate-to-severe adult atopic dermatitis, asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis, and human autoimmune diseases. The company has partnership with GlaxoSmithKline and Bristol-Myers Squibb to develop its product candidates. AnaptysBio is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$63.2 million for the fiscal year ended December 2021 (FY2021), a decrease of 15.8% over FY2020. The operating loss of the company was US$56.8 million in FY2021, compared to an operating loss of US$23.9 million in FY2020. The net loss of the company was US$57.8 million in FY2021, compared to a net loss of US$19.9 million in FY2020. The company reported revenues of US$1.3 million for the third quarter ended September 2022, an increase of 6.3% over the previous quarter.
For a complete picture of Imsidolimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.